Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome
- 1 April 1985
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 88 (4), 1026-1033
- https://doi.org/10.1016/s0016-5085(85)80024-x
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Basis for failure of cimetidine in patients with Zollinger-Ellison syndromeDigestive Diseases and Sciences, 1984
- DURATION OF ACTION OF NEW H2-BLOCKERSThe Lancet, 1984
- Comparison of Ranitidine and Cimetidine in the Treatment of Gastric HypersecretionAnnals of Internal Medicine, 1983
- Diagnosis and Management of the Zollinger-Ellison SyndromeJournal of Clinical Gastroenterology, 1983
- 24 HOUR INTRAGASTRIC ACIDITY AND SINGLE NIGHT-TIME DOSE OF THREE H2-BLOCKERSThe Lancet, 1983
- Kinetics of antisecretory action of a new H2-antagonist, YM-11170, in conscious dogsEuropean Journal of Pharmacology, 1983
- Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortexNature, 1983
- Effect of a new potent H2-receptor antagonist 3[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric mucosal histamine-sensitive adenylate cyclase from guinea pigBiochemical Pharmacology, 1983
- Effect of isopropamide on response to oral cimetidine in patients with Zollinger-Ellison syndromeDigestive Diseases and Sciences, 1982
- H2-Histamine Receptor Blocking Agents in the Zollinger-Ellison SyndromeAnnals of Internal Medicine, 1977